A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.
The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.
After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.
Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.
Cat. No. | 製品名 | CAS No. | Purity | Chemical Structure |
---|---|---|---|---|
T35396 | Spartalizumab (anti-PD-1) | 98% |
|
|
T36652 | Anti-MERS-3A1 mAb | 98% |
|
|
Anti-MERS-3A1 mAb (MERS-3A1) is a high-affinity human monoclonal IgG1 antibody derived from CHO cells. It effectively inhibits the interaction between the MERS-C... | ||||
T39595 | Disitamab vedotin | 2136633-23-1 | 98% |
![]() |
Disitamab vedotin (RC48) is a cleavable antibody-drug conjugate (ADC) that combines a monoclonal antibody targeting human epidermal growth factor receptor 2 (HER... | ||||
T25593 | Labetuzumab govitecan | 1469876-18-3 | 98% |
![]() |
Labetuzumab govitecan is an anti-CEACAM5/SN-38 antibody-drug conjugate for therapy of refractory or relapsing metastatic colorectal cancer. | ||||
T9931 | Meplazumab | 2413715-21-4 | 98% |
|
meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia. | ||||
T39057 | Rozanolixizumab | 1584645-37-3 | 98% |
![]() |
Rozanolixizumab (UCB7665), a humanized high-affinity anti-human neonatal Fc receptor (FcRn) monoclonal antibody (IgG4P), is used to the research of reducing path... | ||||
T35391 | Vibostolimab (anti-TIGIT) | 98% |
|
|
T12706 | Reslizumab | 241473-69-8 | 98% |
![]() |
Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma. | ||||
T36656 | Anti-Spike-RBD Single Domain mAb | 98% |
|
|
The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the... | ||||
T35389 | Sarilumab (anti-IL-6Rα) | 98% |
|
|
T9922 | Matuzumab | 339186-68-4 | 98% |
|
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in ... | ||||
T36655 | Anti-Spike-RBD mAb | 98% |
|
|
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of spike protein and ACE2 is a potential therapeutic approach f... | ||||
T9925 | Ofatumumab | 679818-59-8 | 98% |
|
Ofatumumab is a fully human monoclonal antibody to CD20 which appears to inhibit early-stage B lymphocyte activation | ||||
T36647 | Trastuzumab emtansine | 1018448-65-1 | 98% |
![]() |
Trastuzumab emtansine (Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab wit... | ||||
T35392 | Tiragolumab (anti-TIGIT) | 98% |
|
|
T38951 | Isatuximab | 1461640-62-9 | 98% |
![]() |
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38 , a protein highly expressed on hematological malignant cells, inclu... | ||||
T9928 | Ranibizumab | 347396-82-1 | 98% |
![]() |
Ranibizumab is a humanized monoclonal antibody fragment designed to target and inhibit vascular endothelial growth factor (VEGF), including VEGF110, VEGF121, and... | ||||
T39730 | Datopotamab deruxtecan | 2238831-60-0 | 98% |
![]() |
Datopotamab deruxtecan (DS-1062; Dato-DXd) is an antibody-drug conjugate (ADC) that specifically targets trophoblast cell surface antigen 2 (TROP2). This compoun... | ||||
T10497 | Benralizumab | 1044511-01-4 | 98% |
![]() |
Benralizumab (MEDI-563) is an IL-5Rα-directed cytolytic monoclonal antibody that induces rapid, direct and nearly complete depletion of eosinophils via enhanced ... | ||||
T38105 | Ixekizumab | 1143503-69-8 | 98% |
![]() |
Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A (KD<3 pM). Ixekizumab directly blocks IL... |